{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:42Z","timestamp":1707525342691},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"DOI":"10.7759\/cureus.47005","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:22:21Z","timestamp":1697260941000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Co-transporter Type-2 Inhibitors\u2019 Effect on Quality of Life in Older Adult Population"],"prefix":"10.7759","author":[{"given":"Duygu","family":"Tutan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Erdo\u011fan Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Kayaalp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw JE","year":"2010","unstructured":"Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010, 87:4-14. 10.1016\/j.diabres.2009.10.007","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2020.1737520","article-title":"The assessment and management of quality of life of older adults with diabetes mellitus","volume":"15","author":"Sayyed Kassem L","year":"2020","unstructured":"Sayyed Kassem L, Aron DC. The assessment and management of quality of life of older adults with diabetes mellitus. Expert Rev Endocrinol Metab. 2020, 15:71-81. 10.1080\/17446651.2020.1737520","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-52","article-title":"Multimorbidity and quality of life: a closer look","volume":"5","author":"Fortin M","year":"2007","unstructured":"Fortin M, Dubois MF, Hudon C, Soubhi H, Almirall J. Multimorbidity and quality of life: a closer look. Health Qual Life Outcomes. 2007, 5:52. 10.1186\/1477-7525-5-52","journal-title":"Health Qual Life Outcomes"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/02813430510015296","article-title":"Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries","volume":"23","author":"W\u00e4ndell PE","year":"2005","unstructured":"W\u00e4ndell PE. Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care. 2005, 23:68-74. 10.1080\/02813430510015296","journal-title":"Scand J Prim Health Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2188\/jea.je20130131","article-title":"Health-related quality of life (HRQOL) decreases independently of chronic conditions and geriatric syndromes in older adults with diabetes: the Fujiwara-kyo Study","volume":"24","author":"Nezu S","year":"2014","unstructured":"Nezu S, Okamoto N, Morikawa M, et al.. Health-related quality of life (HRQOL) decreases independently of chronic conditions and geriatric syndromes in older adults with diabetes: the Fujiwara-kyo Study. J Epidemiol. 2014, 24:259-66. 10.2188\/jea.je20130131","journal-title":"J Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12555","article-title":"Health-related quality of life and functional status quality indicators for older persons with multiple chronic conditions","volume":"61","author":"Dy SM","year":"2013","unstructured":"Dy SM, Pfoh ER, Salive ME, Boyd CM. Health-related quality of life and functional status quality indicators for older persons with multiple chronic conditions. J Am Geriatr Soc. 2013, 61:2120-7. 10.1111\/jgs.12555","journal-title":"J Am Geriatr Soc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01504-6","article-title":"The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials","volume":"45","author":"Guo Z","year":"2023","unstructured":"Guo Z, Wang L, Yu J, Wang Y, Yang Z, Zhou C. The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Int J Clin Pharm. 2023, 45:547-55. 10.1007\/s11096-022-01504-6","journal-title":"Int J Clin Pharm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos A","year":"2021","unstructured":"Pawlos A, Broncel M, Wo\u017aniak E, Gorzelak-Pabi\u015b P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021, 26:7213. 10.3390\/molecules26237213","journal-title":"Molecules"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance C","year":"2020","unstructured":"Hierro-Bujalance C, Infante-Garcia C, Del Marco A, et al.. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alzheimers Res Ther. 2020, 12:40. 10.1186\/s13195-020-00607-4","journal-title":"Alzheimers Res Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s1262-3636(14)72693-x","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi S","year":"2014","unstructured":"Halimi S, Verg\u00e8s B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014, 40:28-34. 10.1016\/s1262-3636(14)72693-x","journal-title":"Diabetes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno E","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG, et al.. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021, 44:826-35. 10.2337\/dc20-1464","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2022.03.002","article-title":"SGLT2 inhibitors and safety in older patients","volume":"18","author":"Pollack R","year":"2022","unstructured":"Pollack R, Cahn A. SGLT2 inhibitors and safety in older patients. Heart Fail Clin. 2022, 18:635-43. 10.1016\/j.hfc.2022.03.002","journal-title":"Heart Fail Clin"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-7380-9","article-title":"Development of the WHOQOL-old module","volume":"14","author":"Power M","year":"2005","unstructured":"Power M, Quinn K, Schmidt S. Development of the WHOQOL-old module. Qual Life Res. 2005, 14:2197-214. 10.1007\/s11136-005-7380-9","journal-title":"Qual Life Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1801","article-title":"Diabetes in older adults","volume":"35","author":"Kirkman MS","year":"2012","unstructured":"Kirkman MS, Briscoe VJ, Clark N, et al.. Diabetes in older adults. Diabetes Care. 2012, 35:2650-64. 10.2337\/dc12-1801","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00543-1","article-title":"Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus","volume":"12","author":"Yu DN","year":"2020","unstructured":"Yu DN, Qiu L, Ning SY, Guo LX. Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2020, 12:35. 10.1186\/s13098-020-00543-1","journal-title":"Diabetol Metab Syndr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2014.11.008","article-title":"Management of diabetes in the elderly","volume":"99","author":"Bansal N","year":"2015","unstructured":"Bansal N, Dhaliwal R, Weinstock RS. Management of diabetes in the elderly. Med Clin North Am. 2015, 99:351-77. 10.1016\/j.mcna.2014.11.008","journal-title":"Med Clin North Am"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15173","article-title":"Community program improves quality of life and self-management in older adults with diabetes mellitus and comorbidity","volume":"66","author":"Markle-Reid M","year":"2018","unstructured":"Markle-Reid M, Ploeg J, Fraser KD, et al.. Community program improves quality of life and self-management in older adults with diabetes mellitus and comorbidity. J Am Geriatr Soc. 2018, 66:263-73. 10.1111\/jgs.15173","journal-title":"J Am Geriatr Soc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn A","year":"2020","unstructured":"Cahn A, Mosenzon O, Wiviott SD, et al.. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study. Diabetes Care. 2020, 43:468-75. 10.2337\/dc19-1476","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S012","article-title":"Older adults: Standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Older adults: Standards of medical care in diabetes-2019. Diabetes Care. 2019, 42:S139-47. 10.2337\/dc19-S012","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: The SOLD study","volume":"183","author":"Lunati ME","year":"2022","unstructured":"Lunati ME, Cimino V, Gandolfi A, et al.. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022, 183:106396. 10.1016\/j.phrs.2022.106396","journal-title":"Pharmacol Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1912735","article-title":"Careful use to minimize adverse events of oral antidiabetic medications in the elderly","volume":"22","author":"Scheen AJ","year":"2021","unstructured":"Scheen AJ. Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opin Pharmacother. 2021, 22:2149-65. 10.1080\/14656566.2021.1912735","journal-title":"Expert Opin Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4547-9","article-title":"Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies","volume":"61","author":"Schernthaner G","year":"2018","unstructured":"Schernthaner G, Schernthaner-Reiter MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia. 2018, 61:1503-16. 10.1007\/s00125-018-4547-9","journal-title":"Diabetologia"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial","volume":"48","author":"Monteiro P","year":"2019","unstructured":"Monteiro P, Bergenstal RM, Toural E, et al.. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial. Age Ageing. 2019, 48:859-66. 10.1093\/ageing\/afz096","journal-title":"Age Ageing"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork A","year":"2019","unstructured":"Schork A, Saynisch J, Vosseler A, et al.. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019, 18:46. 10.1186\/s12933-019-0852-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045844","article-title":"Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes","volume":"11","author":"Yabe D","year":"2021","unstructured":"Yabe D, Shiki K, Suzaki K, et al.. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021, 11:e045844. 10.1136\/bmjopen-2020-045844","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus","volume":"37","author":"Kinduryte Schorling O","year":"2020","unstructured":"Kinduryte Schorling O, Clark D, Zwiener I, Kaspers S, Lee J, Iliev H. Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus. Adv Ther. 2020, 37:3463-84. 10.1007\/s12325-020-01329-7","journal-title":"Adv Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1066","article-title":"Diabetes, depression, and quality of life: a population study","volume":"27","author":"Goldney RD","year":"2004","unstructured":"Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004, 27:1066-70. 10.2337\/diacare.27.5.1066","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2018-0345","article-title":"Depression and quality of life in older adults on hemodialysis","volume":"42","author":"Alencar SB","year":"2020","unstructured":"Alencar SB, de Lima FM, Dias LD, et al.. Depression and quality of life in older adults on hemodialysis. Braz J Psychiatry. 2020, 42:195-200. 10.1590\/1516-4446-2018-0345","journal-title":"Braz J Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/197646-sodium-glucose-co-transporter-type-2-inhibitors-effect-on-quality-of-life-in-older-adult-population","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:40Z","timestamp":1707509140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/197646-sodium-glucose-co-transporter-type-2-inhibitors-effect-on-quality-of-life-in-older-adult-population"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.47005","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}